within the promptly evolving area of oncology exploration, correct and productive mutation screening is essential for developing focused therapies. The KRAS Services Platform performs a pivotal role in this landscape by featuring extensive solutions for KRAS mutation profiling and Evaluation. KRAS mutations, found in around ninety five% of RAS-simi